Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 open-label single-dose study of Hemgenix in adolescents with severe or moderately severe hemophilia B
2023-505805-18-00Phase 3Authorised
- Sponsor
- CSL Behring
- Start
- May 2026
- Modality
- Gene Therapies, Recombinant Proteins and Enzymes
- Countries
- 8
01
Overview
Phase 3, open-label, single-arm trial of etranacogene dezaparvovec in hemophilia B (HB), sponsored by CSL Behring. Primary endpoint: Annualized Bleeding Rate. Planned start May 2026; status: authorised.
02
Drugs
etranacogene dezaparvovec
03
Conditions
hemophilia B (HB)
Beyond the preview
Go deeper on 2023-505805-18-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505805-18-00.